EndocrinologyRelacorilant Provides Significant Benefit Across Cardiometabolic Outcomes in Global Statistical Tests of the Placebo-controlled, Randomized-withdrawal GRACE Trial in Cushing SyndromeHand et al. • 2026 • CMHC October 16, 2026
EndocrinologyCharacteristics Associated With Endogenous Hypercortisolism in Individuals With Resistant Hypertension and Cardiovascular Disorders: Analyses From the MOMENTUM StudyAl Dhaybi et al. • 2026 • AHA HTN October 8, 2026
EndocrinologyPrevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension Stratified by Kidney Function: Results From the MOMENTUM StudyDeFronzo et al. • 2026 • Heart in Diabetes June 22, 2026
OncologyEfficacy and Safety of Relacorilant + Nab-paclitaxel in Patients Aged ≥65 Years With Platinum-resistant Ovarian Cancer (PROC) in the Phase 3 ROSELLA Study (GOG-3073, ENGOT-OV72, APGOT-Ov10)Lorusso et al. • 2026 • ESMO Gyn June 18, 2026
OncologyReal-World Comparative Effectiveness of Nab-paclitaxel and Standard of Care Chemotherapies in Patients With Platinum-Resistant Ovarian Cancer (COMPASS 2.0)Shahin et al. • 2026 • ESMO Gyn June 18, 2026
EndocrinologyEndogenous Hypercortisolism in Individuals With Resistant Hypertension and Difficult-to-Control Type 2 Diabetes: Results From Two Large, Prospective StudiesDeFronzo et al. • 2026 • ENDO June 15, 2026
EndocrinologyCharacterization of Individuals With Resistant Hypertension and Post-Dexamethasone Suppression Test Cortisol <1.2, 1.2–1.8, and >1.8 μg/dL: Results From the MOMENTUM StudyEilerman et al. • 2026 • ENDO June 15, 2026
EndocrinologyHigh Prevalence of Endogenous Hypercortisolism in Patients With Type 2 Diabetes and Resistant Hypertension: Results From the MOMENTUM StudyUmpierrez et al. • 2026 • ADA June 8, 2026
EndocrinologyEffects of Mifepristone in People With Difficult-to-Control T2D and Hypercortisolism on GLP-1 RAsSloan et al. • 2026 • ADA June 6, 2026
OncologySYNERGY: A Phase 1b/2 Study of Nenocorilant, a Selective Glucocorticoid Receptor Antagonist, Plus Nivolumab in Patients With Advanced Solid MalignanciesHamid et al. • 2026 • ASCO May 30, 2026
